Search results for "high-dose chemotherapy"

showing 4 items of 4 documents

Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experienc…

2020

Background Malignant germ cell tumors (GCTs) are a heterogeneous group of rare neoplasms in children. Optimal outcome is achieved with multimodal therapies for patients with both localized and advanced disease, especially after the introduction of platinum-based chemotherapy regimens. In this respect, data on salvage treatment for children with relapsed or platinum-refractory disease are still limited. Methods Retrospective analysis of data regarding patients affected by malignant GCTs with platinum-refractory or relapsed disease after first-line treatment according to AIEOP TCGM 2004 protocol was conducted. Results Twenty-one patients, 15 females and 6 males, were considered for the analys…

OncologyMelphalanMalemedicine.medical_treatmentDrug ResistanceSalvage therapyrelapsed tumorsDeoxycytidineCarboplatinchemistry.chemical_compound0302 clinical medicineNeoplasmsAntineoplastic Combined Chemotherapy Protocolsgerm cell tumorsChildEtoposideIfosfamideRemission InductionHematologyNeoplasms Germ Cell and EmbryonalPrognosisgerm cell tumors; high-dose chemotherapy; pediatric tumors; refractory tumors; relapsed tumors; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child Preschool; Cisplatin; Deoxycytidine; Drug Resistance Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence Local; Neoplasms Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Salvage Therapypediatric tumorsOxaliplatinSurvival RateLocalOncology030220 oncology & carcinogenesisChild PreschoolFemalerefractory tumorsmedicine.drugmedicine.medical_specialtyAdolescentPaclitaxelThioTEPA03 medical and health sciencesInternal medicinemedicineHumansIfosfamidePreschoolSurvival rateRetrospective StudiesSalvage TherapyChemotherapybusiness.industryInfantmedicine.diseaseGemcitabineCarboplatinNeoplasm RecurrencechemistryDrug Resistance NeoplasmPediatrics Perinatology and Child HealthSettore MED/20NeoplasmGerm Cell and EmbryonalGerm cell tumorsCisplatinNeoplasm Recurrence Localbusinesshigh-dose chemotherapy030215 immunologyFollow-Up StudiesPediatric bloodcancerREFERENCES
researchProduct

Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: …

2016

Background. Following high-dose chemotherapy/bone marrow transplantation, patients are routinely, prophylactically transfused with platelet concentrates (PC) if they have a platelet count ≤10×109/L or higher in the presence of risk factors for bleeding. However, whether such transfusions are necessary in clinically stable patients with no bleeding, or whether a therapeutic transfusion strategy could be sufficient and safe, is still debated. Materials and methods. The GIMEMA Haemostasis and Thrombosis Working Party sent a questionnaire to Italian haematology departments to survey several aspects of daily platelet transfusion practice, such as the cut-off platelet count for transfusion, the e…

Settore MED/15 - MALATTIE DEL SANGUEBone marrow transplantationProphylaxisBleeding; Bone marrow transplantation; High-dose chemotherapy; Platelet transfusion; Prophylaxis; Immunology and Allergy; HematologyBleedingHigh-dose chemotherapybleeding platelet transfusion prophylaxis high-dose chemotherapy bone marrow transplantationImmunology and AllergyOriginal ArticleHematologyProphylaxiPlatelet transfusion
researchProduct

Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell su…

2008

Background We evaluated an intensified chemotherapy strategy in children with Wilms tumor who relapsed with high-risk features. Procedures From January 2001 to June 2006, we treated 20 consecutive children with reinduction chemotherapy (using ifosfamide/carboplatin/etoposide in 15/20 cases), with (n = 15) or without (n = 5) subsequent high-dose chemotherapy and hematopoietic stem cell support, surgery where feasible, and radiation therapy. The median time to relapse was 10 months after nephrectomy. All but two children initially received doxorubicin as first-line therapy. Results All patients were assessed for outcome: 13 are currently alive, 12 of them in remission a median 25 months since…

OncologyMaleTransplantation Conditioningmedicine.medical_treatmentHematopoietic stem cell transplantationNephrectomyPediatricschemistry.chemical_compoundHigh-dose chemotherapyRelapseChildIfosfamideGraft SurvivalRemission InductionHematopoietic Stem Cell TransplantationHematologyPerinatology and Child HealthSurvival RateTreatment OutcomeItalyOncologyChild PreschoolAbsolute neutrophil countFemaleAutologousmedicine.drugmedicine.medical_specialtyAntineoplastic AgentsTransplantation AutologousWilms TumorInternal medicinemedicineHumansPreschoolSurvival rateSalvage TherapyChemotherapyTransplantationbusiness.industryInfantWilms' tumormedicine.diseaseCarboplatinSurgeryRadiation therapychemistryPediatrics Perinatology and Child HealthAutologous hematopoietic stem cell transplantation; High-dose chemotherapy; Relapse; Wilms tumor; Antineoplastic Agents; Child; Child Preschool; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Infant; Italy; Male; Nephrectomy; Remission Induction; Salvage Therapy; Survival Rate; Transplantation Conditioning; Transplantation Autologous; Treatment Outcome; Wilms Tumor; Pediatrics Perinatology and Child Health; Hematology; OncologybusinessAutologous hematopoietic stem cell transplantation
researchProduct

Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT…

2021

Abstract Background Embryonal tumors with multilayered rosettes (ETMR) are highly aggressive tumors occurring in early childhood. Published clinical data refer to retrospective, heterogeneously treated cohorts. Here, we describe the outcome of patients treated according to the prospective P-HIT trial and subsequent HIT2000-interim-registry. Patients and methods Age-stratified treatment included carboplatin/etoposide induction, tandem high-dose chemotherapy (“CARBO/ETO + HDCT”), and response-stratified radiotherapy. Patients with centrally reviewed neuropathological and molecularly confirmed diagnosis of ETMR recruited within the P-HIT trial (2001-2011; n = 19), the HIT2000-interim-registry …

OncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentMedizinClinical InvestigationsImproved survival610 Medicine & healthBrain Neoplasms/drug therapyCentral Nervous System NeoplasmsHigh dose chemotherapychemistry.chemical_compoundCarboplatin/therapeutic useInternal medicinemedicineHigh-dose chemotherapyHumansNeuroectodermal Tumors Primitive1306 Cancer ResearchProspective StudiesChildOutcomeEtoposideRetrospective StudiesChemotherapyddc:618business.industryBrain NeoplasmsIncidence (epidemiology)IncidenceInfantInduction ChemotherapyNeoplasms Germ Cell and EmbryonalCarboplatinETMRRadiation therapyClinical trialClinical trial2728 Neurology (clinical)Oncologychemistry10036 Medical ClinicChild Preschool2730 OncologyNeurology (clinical)Antineoplastic Combined Chemotherapy Protocols/therapeutic usebusinessCarboplatin/etoposideNeoplasms Germ Cell and Embryonal/drug therapy
researchProduct